J Rheum Dis.  2022 Oct;29(4):193-199. 10.4078/jrd.22.0023.

The Epidemiology and Treatment of Ankylosing Spondylitis in Korea

• Kwon SR
• Kim TH
• Kim TJ
• Park W
• Shim SC

• KMID: 2533620
• DOI: http://doi.org/10.4078/jrd.22.0023

Abstract

Ankylosing spondylitis is a chronic inflammatory disorder characterized by inflammation of the axial skeleton and sacroiliac joints and to a lesser extent by peripheral arthritis and the involvement of some extra-articular organs. It is paramount for the provision of effective health care delivery to be familiar with the epidemiologic studies on prevalence, mortality, and disability. Furthermore, there is no systematic arrangement of studies related to the treatment of ankylosing spondylitis in Korea. In this review, we addressed Korean ankylosing spondylitis epidemiological studies related to prevalence, genetic factor especially human leucocyte antigen-B27, extra-articular manifestations, infections, mortality, radiologic progression, child-birth, and quality of life. Furthermore, we reviewed Korean ankylosing spondylitis treatment researches about treatment trend, patients’ registration program called The KOrean College of Rheumatology BIOlogics and targeted therapy (KOBIO) registry project, biologics and biosimiliars, complications especially infections, and issues about bony progression. There would be value to further studying the epidemiology and treatment of Korean ankylosing spondylitis.

Keyword

Ankylosing spondylitis; Epidemiology; Treatment; Korea

Reference

1. Park PR, Jo S, Jin SH, Kim TJ. 2020; MicroRNA-10b plays a role in bone formation by suppressing interleukin-22 in ankylosing spondylitis. J Rheum Dis. 27:61–7. DOI: 10.4078/jrd.2020.27.1.61.

2. Olivieri I, van Tubergen A, Salvarani C, van der Linden S. 2002; Seronegative spondyloarthritides. Best Pract Res Clin Rheumatol. 16:723–39. DOI: 10.1053/berh.2002.0263. PMID: 12473270.

3. Boonen A, van der Linden SM. 2006; The burden of ankylosing spondylitis. J Rheumatol Suppl. 78:4–11.

4. Akkoc N. 2008; Are spondyloarthropathies as common as rheumatoid arthritis worldwide? A review. Curr Rheumatol Rep. 10:371–8. DOI: 10.1007/s11926-008-0060-3. PMID: 18817640.

5. Braun J, Sieper J. 2007; Ankylosing spondylitis. Lancet. 369:1379–90. DOI: 10.1016/S0140-6736(07)60635-7.

6. Montacer Kchir M, Mehdi Ghannouchi M, Hamdi W, Azzouz D, Kochbati S, Saadellaoui K, et al. 2009; Impact of the ankylosing spondylitis on the professional activity. Joint Bone Spine. 76:378–82. DOI: 10.1016/j.jbspin.2008.08.010. PMID: 19525138.

7. Ahn SM, Kim YG. 2021; Biologic therapies for the treatment of ankylosing spondylitis. J Korean Med Assoc. 64:116–23. DOI: 10.5124/jkma.2021.64.2.116.

8. Park JS, Hong JY, Park YS, Han K, Suh SW. 2018; Trends in the prevalence and incidence of ankylosing spondylitis in South Korea, 2010-2015 and estimated differences according to income status. Sci Rep. 8:7694. DOI: 10.1038/s41598-018-25933-4. PMID: 29769560. PMCID: PMC5955990.

9. Dans LF, Tankeh-Torres S, Amante CM, Penserga EG. 1997; The prevalence of rheumatic diseases in a Filipino urban population: a WHO-ILAR COPCORD Study. World Health Organization. International League of Associations for Rheumatology. Community Oriented Programme for the Control of the Rheumatic Diseases. J Rheumatol. 24:1814–9.

10. Chou CT, Pei L, Chang DM, Lee CF, Schumacher HR, Liang MH. 1994; Prevalence of rheumatic diseases in Taiwan: a population study of urban, suburban, rural differences. J Rheumatol. 21:302–6.

11. Hukuda S, Minami M, Saito T, Mitsui H, Matsui N, Komatsubara Y, et al. 2001; Spondyloarthropathies in Japan: nationwide questionnaire survey performed by the Japan Ankylosing Spondylitis Society. J Rheumatol. 28:554–9.

12. Kim JJ, Kwon EJ, Shim SC, Kim TH. 2012; Frequency of human leukocyte antigen-B27 in Korean. J Rheum Dis. 19:112–3. DOI: 10.4078/jrd.2012.19.2.112.

13. Khan MA. Mehra NK, Kaur G, McCluskey J, Christiansen FT, Claas FH, editors. 2010. The HLA complex in biology and medicine: a resource book. Jaypee Brothers Medical Publishers;New Delhi: p. 259–75. DOI: 10.5005/jp/books/11170_16.

14. Whang DH, Yang YS, Hong HK. 2008; Allele and haplotype frequencies of human leukocyte antigen-A, -B, and -DR loci in Koreans: DNA typing of 1,500 cord blood units. Korean J Lab Med. 28:465–74. DOI: 10.3343/kjlm.2008.28.6.465. PMID: 19127112.

15. Khan MA, Mathieu A, Sorrentino R, Akkoc N. 2007; The pathogenetic role of HLA-B27 and its subtypes. Autoimmun Rev. 6:183–9. DOI: 10.1016/j.autrev.2006.11.003. PMID: 17289555.

16. Park SH, Kim J, Kim SG, Kim SK, Chung WT, Choe JY. 2009; Human leucocyte antigen-B27 subtypes in Korean patients with ankylosing spondylitis: higher B*2705 in the patient group. Int J Rheum Dis. 12:34–8. DOI: 10.1111/j.1756-185X.2009.01377.x. PMID: 20374314.

17. Chavan H, Samant R, Deshpande A, Mankeshwar R. 2011; Correlation of HLA B27 subtypes with clinical features of ankylosing spondylitis. Int J Rheum Dis. 14:369–74. DOI: 10.1111/j.1756-185X.2011.01635.x. PMID: 22004234.

18. Liu Y, Jiang L, Cai Q, Danoy P, Barnardo MC, Brown MA, et al. 2010; Predominant association of HLA-B*2704 with ankylosing spondylitis in Chinese Han patients. Tissue Antigens. 75:61–4. DOI: 10.1111/j.1399-0039.2009.01379.x. PMID: 19804562.

19. López-Larrea C, Sujirachato K, Mehra NK, Chiewsilp P, Isarangkura D, Kanga U, et al. 1995; HLA-B27 subtypes in Asian patients with ankylosing spondylitis. Evidence for new associations. Tissue Antigens. 45:169–76. DOI: 10.1111/j.1399-0039.1995.tb02436.x. PMID: 7761976.

20. Nasution AR, Mardjuadi A, Kunmartini S, Suryadhana NG, Setyohadi B, Sudarsono D, et al. 1997; HLA-B27 subtypes positively and negatively associated with spondyloarthropathy. J Rheumatol. 24:1111–4.

21. Cipriani A, Rivera S, Hassanhi M, Márquez G, Hernández R, Villalobos C, et al. 2003; HLA-B27 subtypes determination in patients with ankylosing spondylitis from Zulia, Venezuela. Hum Immunol. 64:745–9. DOI: 10.1016/S0198-8859(03)00085-5.

22. Lee SH, Choi IA, Lee YA, Park EK, Kim YH, Kim KS, et al. 2008; Human leukocyte antigen-B*2705 is the predominant subtype in the Korean population with ankylosing spondylitis, unlike in other Asians. Rheumatol Int. 29:43–6. DOI: 10.1007/s00296-008-0602-z. PMID: 18493767.

23. Lee JS, Oh BL, Lee HY, Song YW, Lee EY. 2018; Comorbidity, disability, and healthcare expenditure of ankylosing spondylitis in Korea: a population-based study. PLoS One. 13:e0192524. DOI: 10.1371/journal.pone.0192524. PMID: 29420599. PMCID: PMC5805317.

24. Stolwijk C, Essers I, van Tubergen A, Boonen A, Bazelier MT, De Bruin ML, et al. 2015; The epidemiology of extra-articular manifestations in ankylosing spondylitis: a population-based matched cohort study. Ann Rheum Dis. 74:1373–8. DOI: 10.1136/annrheumdis-2014-205253. PMID: 24658834.

25. Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A. 2015; Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis. 74:65–73. DOI: 10.1136/annrheumdis-2013-203582. PMID: 23999006.

26. Kim TJ, Kim TH. 2010; Clinical spectrum of ankylosing spondylitis in Korea. Joint Bone Spine. 77:235–40. DOI: 10.1016/j.jbspin.2009.11.015. PMID: 20356776.

27. Kim TJ, Lee S, Joo KB, Park DJ, Park YW, Lee SS, et al. 2014; The presence of peripheral arthritis delays spinal radiographic progression in ankylosing spondylitis: Observation Study of the Korean Spondyloarthropathy Registry. Rheumatology (Oxford). 53:1404–8. DOI: 10.1093/rheumatology/keu014. PMID: 24609061.

28. Kim TJ, Shin JH, Sung IH, Lee S, Song Y, Kim TH. 2016; Comparison on radiographic progression for 5 years between juvenile onset ankylosing spondylitis and adult onset ankylosing spondylitis: an observational study of the Korean SpondyloArthropathy Registry (OSKAR) data. Clin Exp Rheumatol. 34:668–72.

29. Kook H, Jin SH, Lee S, Lee SJ, Kim TH, Kim TJ. 2020; Radiographic progression in patients with ankylosing spondylitis according to uveitis based on the Observation Study of Korean Spondyloarthropathy Registry. Arch Rheumatol. 35:1–6. DOI: 10.5606/ArchRheumatol.2020.7095. PMID: 32637913. PMCID: PMC7322302.

30. Bae KH, Hong JB, Choi YJ, Jung JH, Han IB, Choi JM, et al. 2019; Association of congestive heart failure and death with ankylosing spondylitis: a nationwide longitudinal cohort study in Korea. J Korean Neurosurg Soc. 62:217–24. DOI: 10.3340/jkns.2018.0110. PMID: 30840977. PMCID: PMC6411571.

31. Libby P, Ridker PM, Hansson GK. 2009; Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 54:2129–38. DOI: 10.1016/j.jacc.2009.09.009. PMID: 19942084. PMCID: PMC2834169.

32. Min HK, Lee J, Ju JH, Kwok SK, Youn HJ, Park SH. 2020; Echocardiographic evaluation of axial spondyloarthritis in Korea: data from the Catholic Axial Spondyloarthritis Cohort. J Rheum Dis. 27:30–6. DOI: 10.4078/jrd.2020.27.1.30.

33. Albanese I, Khan K, Barratt B, Al-Kindi H, Schwertani A. 2018; Atherosclerotic calcification: Wnt is the hint. J Am Heart Assoc. 7:e007356. DOI: 10.1161/JAHA.117.007356. PMID: 29437603. PMCID: PMC5850186.

34. Zochling J, Braun J. 2008; Mortality in ankylosing spondylitis. Clin Exp Rheumatol. 26(5 Suppl 51):S80–4.

35. Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV. 2006; Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 33:2167–72.

36. Kwon OC, Park MC. 2022; Effect of tumor necrosis factor inhibitors on risk of cardiovascular disease in patients with axial spondyloarthritis. Arthritis Res Ther. 24:141. DOI: 10.1186/s13075-022-02836-4. PMID: 35698171. PMCID: PMC9190158.

37. Lim DH, Kim YJ, Kim SO, Hong S, Lee CK, Yoo B, et al. 2018; The risk of herpes zoster in patients with ankylosing spondylitis: analysis of the Korean National Health Insurance Service - Sample cohort database. Mod Rheumatol. 28:168–73. DOI: 10.1080/14397595.2017.1325034. PMID: 28548546.

38. Wang S, Wei JC, Huang JY, Perng WT, Zhang Z. 2020; The risk of herpes zoster among patients with ankylosing spondylitis: a population-based cohort study in Taiwan. Int J Rheum Dis. 23:181–8. DOI: 10.1111/1756-185X.13650. PMID: 31334604.

39. Koo BS, Lim YC, Lee MY, Jeon JY, Yoo HJ, Oh IS, et al. 2021; The risk factors and incidence of major infectious diseases in patients with ankylosing spondylitis receiving tumor necrosis factor inhibitors. Mod Rheumatol. 31:1192–201. DOI: 10.1080/14397595.2021.1878985. PMID: 33494621.

40. Park EH, Lee JS, Kim YJ, Lee SM, Jun JK, Lee EB, et al. 2021; Pregnancy outcomes in Korean women with ankylosing spondylitis. Korean J Intern Med. 36:721–30. DOI: 10.3904/kjim.2019.144. PMID: 31556255. PMCID: PMC8137399.

41. Jakobsson GL, Stephansson O, Askling J, Jacobsson LT. 2016; Pregnancy outcomes in patients with ankylosing spondylitis: a nationwide register study. Ann Rheum Dis. 75:1838–42. DOI: 10.1136/annrheumdis-2015-207992. PMID: 26698845.

42. Nam B, Koo BS, Nam SW, Shin JH, Song Y, Cho SK, et al. 2021; Gender differences in factors associated with low quality of life and depression in Korean patients with ankylosing spondylitis. Qual Life Res. 30:2299–310. DOI: 10.1007/s11136-021-02800-w. PMID: 33689133.

43. Park JS, Hong JY, Kim HK, Koo B, Kim SH, Kwon YC. 2020; National pharmacological treatment trends for ankylosing spondylitis in South Korea: a national health insurance database study. PLoS One. 15:e0240155. DOI: 10.1371/journal.pone.0240155. PMID: 33021982. PMCID: PMC7537903.

44. Koo BS, Lim YC, Lee MY, Jeon JY, Yoo HJ, Oh IS, et al. 2021; Dose reduction of tumor necrosis factor inhibitor and its effect on medical costs for patients with ankylosing spondylitis. Rheumatol Ther. 8:347–59. DOI: 10.1007/s40744-020-00274-9. PMID: 33420967. PMCID: PMC7991020.

45. Choi CB, Kim TJ, Park HJ, Uhm WS, Jun JB, Bae SC, et al. 2008; Safety and clinical responses in ankylosing spondylitis after three months of etanercept therapy. J Korean Med Sci. 23:852–6. DOI: 10.3346/jkms.2008.23.5.852. PMID: 18955793. PMCID: PMC2580004.

46. Kim J, Koh JH, Choi SJ, Jeon CH, Kwok SK, Kim SK, et al. 2021; KOBIO, the first web-based Korean biologics registry operated with a unified platform among distinct disease entities. J Rheum Dis. 28:176–82. DOI: 10.4078/jrd.2021.28.4.176.

47. Kwon M, Joung CI, Shin H, Lee SM, Lee CC, Lee YJ, et al. 4040. Signal detection of unknown adverse drug reactions of biologic DMARDs using real-world data from the Korean College of Rheumatology BIOlogics & Targeted Therapy Registry (KOBIO). https://doi.org/10.2139/ssrn.4040132. cited 2022 Mar 28. DOI: 10.2139/ssrn.4040132.

48. Kim H, Kim J, Shin K, Ko S. 2017; Patterns of biologics use in ankylosing spondylitis and psoriatic arthritis patients in Korea. Value Health. 20:A541. DOI: 10.1016/j.jval.2017.08.809.

49. Min HK, Kim HR, Lee SH, Hong YS, Kim MY, Park SH, et al. 2022; Feb. 2. Clinical efficacy of alternative TNF inhibitor and secukinumab between primary non-responder and secondary non-responder of prior TNF inhibitor in ankylosing spondylitis. Mod Rheumatol. [Epub]. DOI:10.1093/mr/roac005. DOI: 10.1093/mr/roac005. PMID: 35107167.

50. Kim TH, Lee SS, Park W, Song YW, Suh CH, Kim S, et al. 2020; A 5-year retrospective analysis of drug survival, safety, and effectiveness of the infliximab biosimilar CT-P13 in patients with rheumatoid arthritis and ankylosing spondylitis. Clin Drug Investig. 40:541–53. DOI: 10.1007/s40261-020-00907-5. PMID: 32328979.

51. Kim HW, Kwon SR, Jung KH, Kim SK, Baek HJ, Seo MR, et al. 2016; Safety of resuming tumor necrosis factor inhibitors in ankylosing spondylitis patients concomitant with the treatment of active tuberculosis: a retrospective nationwide registry of the Korean Society of Spondyloarthritis Research. PLoS One. 11:e0153816. DOI: 10.1371/journal.pone.0153816. PMID: 27101309. PMCID: PMC4839632.

52. Baraliakos X, Listing J, Rudwaleit M, Haibel H, Brandt J, Sieper J, et al. 2007; Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis. 66:910–5. DOI: 10.1136/ard.2006.066415. PMID: 17329306. PMCID: PMC1955120.

53. van Tubergen A, Ramiro S, van der Heijde D, Dougados M, Mielants H, Landewé R. 2012; Development of new syndesmophytes and bridges in ankylosing spondylitis and their predictors: a longitudinal study. Ann Rheum Dis. 71:518–23. DOI: 10.1136/annrheumdis-2011-200411. PMID: 21989544.

54. Landewé R, Dougados M, Mielants H, van der Tempel H, van der Heijde D. 2009; Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. Ann Rheum Dis. 68:863–7. DOI: 10.1136/ard.2008.091793. PMID: 18628283.

55. Machado P, Landewé R, Braun J, Hermann KG, Baker D, van der Heijde D. 2010; Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Ann Rheum Dis. 69:1465–70. DOI: 10.1136/ard.2009.124206. PMID: 20498215.

56. Lee TH, Koo BS, Nam B, Oh JS, Park SY, Lee S, et al. 2020; Conventional disease-modifying antirheumatic drugs therapy may not slow spinal radiographic progression in ankylosing spondylitis: results from an 18-year longitudinal dataset. Ther Adv Musculoskelet Dis. 12:1759720X20975912. DOI: 10.1177/1759720X20975912. PMID: 33294039. PMCID: PMC7705797.

57. van der Heijde D, Landewé R, Baraliakos X, Houben H, van Tubergen A, Williamson P, et al. 2008; Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum. 58:3063–70. DOI: 10.1002/art.23901. PMID: 18821688.

58. van der Heijde D, Landewé R, Einstein S, Ory P, Vosse D, Ni L, et al. 2008; Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum. 58:1324–31. DOI: 10.1002/art.23471. PMID: 18438853.

59. van der Heijde D, Salonen D, Weissman BN, Landewé R, Maksymowych WP, Kupper H, et al. 2009; Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther. 11:R127. DOI: 10.1186/ar2794. PMID: 19703304. PMCID: PMC2745811.

60. Koo BS, Oh JS, Park SY, Shin JH, Ahn GY, Lee S, et al. 2020; Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis: 18-year real-world evidence. Ann Rheum Dis. 79:1327–32. DOI: 10.1136/annrheumdis-2019-216741. PMID: 32660979.

61. Park JW, Kim MJ, Lee JS, Ha YJ, Park JK, Kang EH, et al. 2019; Impact of tumor necrosis factor inhibitor versus nonsteroidal antiinflammatory drug treatment on radiographic progression in early ankylosing spondylitis: its relationship to inflammation control during treatment. Arthritis Rheumatol. 71:82–90. DOI: 10.1002/art.40661. PMID: 29984487. PMCID: PMC6587468.